KYMR NASDAQ
Kymera Therapeutics, Inc.
1W: +3.6%
1M: +5.0%
3M: +11.7%
YTD: +61.6%
1Y: +100.8%
3Y: +867.6%
5Y: +112.8%
$117.57
+2.73 (+2.38%)
Weekly Expected Move ±5.5%
$99
$105
$111
$117
$123
Credit Risk of going bust: lower than 78% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.67B.
Distance to default 9.29 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.67B.
Distance to default 9.29 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-12-27
Earliest Filing
2026-02-26
Latest Filing
investor: 4
partner: 2
supplier: 1
Counterparties (Filed by KYMR)
7 relationshipsCompanies named in KYMR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Terminated the prior Open Market Sale Agreement effective immediately. | 2026-02-26 | View |
| Baker Brothers Life Sciences, L.P. | — | investor | Signatory to registration rights agreement | 2025-06-27 | View |
| 667, L.P. | — | investor | Signatory to registration rights agreement | 2025-06-27 | View |
| Atlas Venture | — | investor | Affiliated entity holding registrable securities | 2025-06-27 | View |
| BVF Partners L.P. | — | investor | Affiliated entity holding registrable securities | 2025-06-27 | View |
| Sanofi S.A. | SNYNF | partner | Collaboration partner providing a $15 million milestone payment | 2024-01-05 | View |
| ARE-MA REGION NO. 75, LLC | — | supplier | Lease agreement for office and laboratory space | 2021-12-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-25 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-24 | Shareholder Vote | View | |
| 2026-06-08 | Officer/Director Change | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-03-27 | Bylaws Amendment; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-26 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Other Events | Agreement | View |
| 2026-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-10 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-08 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-03 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-27 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-27 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-06-25 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-25 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR